When does AbbVie Inc. (ABBV) report earnings? On Oct 30, 2026, before the open
Of its last 12 earnings announcements: 12 during market hours. Each one comes from the 8-K with item 2.02 that AbbVie filed with the SEC, paired with the 10-Q or 10-K for that same quarter: 54 quarters since Apr 26, 2013, and every row links to its filing.
Next announced date: Oct 30, 2026, before the open. It comes from the company through the public Nasdaq calendar, not from the SEC: it is a scheduled date and companies do move it. Everything else on this page already happened, with its filing attached.
The latest, still without a report
- Oct 5, 2026, Monday at 20:07 New York time (after the close). see the 8-K
It is this company's most recent 8-K with item 2.02 and it does not yet have its 10-Q or 10-K behind it, so there is no way to say which quarter it belongs to: it does not enter the figures above or the table, and for the same reason it might not be an earnings announcement at all (some companies use this same item for production figures or monthly sales).
The last 20 quarters, one by one
"Lead": trading sessions between the announcement and the full quarterly report to the SEC (10-Q, or 10-K at fiscal year end). For AbbVie, a median of 6.5 sessions over the last 12 quarters.
| Announcement | Day | Time (NY) | Session | Quarter ended | SEC report | Lead | Filing |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | Friday | 11:51 | during market hours | Jun 30, 2026 | 10-Q · Aug 3, 2026 | 1 session | 8-K |
| Apr 29, 2026 | Wednesday | 11:50 | during market hours | Mar 31, 2026 | 10-Q · May 8, 2026 | 7 sessions | 8-K |
| Feb 4, 2026 | Wednesday | 12:54 | during market hours | Dec 31, 2025 | 10-K · Feb 20, 2026 | 11 sessions | 8-K |
| Oct 31, 2025 | Friday | 11:51 | during market hours | Sep 30, 2025 | 10-Q · Nov 4, 2025 | 2 sessions | 8-K |
| Jul 31, 2025 | Thursday | 11:48 | during market hours | Jun 30, 2025 | 10-Q · Aug 4, 2025 | 2 sessions | 8-K |
| Apr 25, 2025 | Friday | 11:48 | during market hours | Mar 31, 2025 | 10-Q · May 9, 2025 | 10 sessions | 8-K |
| Jan 31, 2025 | Friday | 12:42 | during market hours | Dec 31, 2024 | 10-K · Feb 14, 2025 | 10 sessions | 8-K |
| Oct 30, 2024 | Wednesday | 11:43 | during market hours | Sep 30, 2024 | 10-Q · Nov 4, 2024 | 3 sessions | 8-K |
| Jul 25, 2024 | Thursday | 11:41 | during market hours | Jun 30, 2024 | 10-Q · Aug 7, 2024 | 9 sessions | 8-K |
| Apr 26, 2024 | Friday | 11:43 | during market hours | Mar 31, 2024 | 10-Q · May 3, 2024 | 5 sessions | 8-K |
| Feb 2, 2024 | Friday | 12:51 | during market hours | Dec 31, 2023 | 10-K · Feb 20, 2024 | 11 sessions | 8-K |
| Oct 27, 2023 | Friday | 11:49 | during market hours | Sep 30, 2023 | 10-Q · Nov 6, 2023 | 6 sessions | 8-K |
| Jul 27, 2023 | Thursday | 11:45 | during market hours | Jun 30, 2023 | 10-Q · Aug 7, 2023 | 7 sessions | 8-K |
| Apr 27, 2023 | Thursday | 11:36 | during market hours | Mar 31, 2023 | 10-Q · May 5, 2023 | 6 sessions | 8-K |
| Feb 9, 2023 | Thursday | 12:55 | during market hours | Dec 31, 2022 | 10-K · Feb 17, 2023 | 6 sessions | 8-K |
| Oct 28, 2022 | Friday | 11:48 | during market hours | Sep 30, 2022 | 10-Q · Nov 4, 2022 | 5 sessions | 8-K |
| Jul 29, 2022 | Friday | 11:49 | during market hours | Jun 30, 2022 | 10-Q · Aug 4, 2022 | 4 sessions | 8-K |
| Apr 29, 2022 | Friday | 11:45 | during market hours | Mar 31, 2022 | 10-Q · May 6, 2022 | 5 sessions | 8-K |
| Feb 2, 2022 | Wednesday | 12:48 | during market hours | Dec 31, 2021 | 10-K · Feb 18, 2022 | 12 sessions | 8-K |
| Oct 29, 2021 | Friday | 11:42 | during market hours | Sep 30, 2021 | 10-Q · Nov 2, 2021 | 2 sessions | 8-K |
The table shows the 20 most recent quarters. All 54 are in the CSV, with the same columns and one row per quarter.
Download all 54 ABBV quarters as CSV → Free, no account.
How AbbVie shares moved on their latest earnings
Over the 8 announcements with prices in this table, ABBV rose 4 times and fell 4 times; the median move, ignoring sign, was 3.5%, against 0.4% for SPY over the same windows. The largest, +6.4%, came with the results of Oct 30, 2024. Reported EPS beat the consensus estimate in 4 of the 5 quarters with an estimate.
| Announcement | Session | Window, close to close | ABBV | SPY | EPS actual / expected |
|---|---|---|---|---|---|
| Jul 31, 2026 | during market hours | Jul 30, 2026 → Jul 31, 2026 | −2.5% | +0.7% | 3.65 / 3.61 (+1.2%) |
| Apr 29, 2026 | during market hours | Apr 28, 2026 → Apr 29, 2026 | +3.1% | 0% | 2.65 / 2.67 (−0.8%) |
| Feb 4, 2026 | during market hours | Feb 3, 2026 → Feb 4, 2026 | −3.8% | −0.5% | 2.71 / 2.65 (+2.2%) |
| Oct 31, 2025 | during market hours | Oct 30, 2025 → Oct 31, 2025 | −4.5% | +0.3% | 1.86 / 1.78 (+4.2%) |
| Jul 31, 2025 | during market hours | Jul 30, 2025 → Jul 31, 2025 | −0.2% | −0.4% | 2.97 / 2.91 (+2.1%) |
| Apr 25, 2025 | during market hours | Apr 24, 2025 → Apr 25, 2025 | +3.2% | +0.7% | |
| Jan 31, 2025 | during market hours | Jan 30, 2025 → Jan 31, 2025 | +4.7% | −0.5% | |
| Oct 30, 2024 | during market hours | Oct 29, 2024 → Oct 30, 2024 | +6.4% | −0.3% |
ABBV window: when it reported before the open or during market hours, from the previous close to that day's. Split-adjusted closes and EPS with its estimate, from Yahoo Finance. It already happened: it does not anticipate the next announcement.
Where each number comes from
From the 8-K with item 2.02 ("Results of Operations and Financial Condition") that AbbVie filed on EDGAR, the SEC's public database; only those with their 10-Q or 10-K behind them count, so other 8-Ks with the same item (production figures, monthly sales) stay out. The time is converted to New York time using this specific company's stamp convention (its EDGAR stamp arrives in UTC), and it is not assumed: it is derived from the hours in which EDGAR accepts filings.
What this data does not know
- The exact time of the press release: the 8-K reaches EDGAR minutes or hours later, so AbbVie's median 11:50 is an upper bound. The session says which one the news landed in, not what minute it was said.
- Nothing before Apr 26, 2013: it is AbbVie's oldest quarter with announcement and report paired in the file.
- What will happen. The page's only future date, Oct 30, 2026, was announced by AbbVie on the Nasdaq calendar and can be moved. AbbVie reporting during market hours 54 quarters in a row does not say the next one will be the same.
- AbbVie's identity is its SEC CIK (0001551152), not its symbol: symbols get recycled and renamed.
When other Healthcare companies report earnings
- MRNA
- LLY
- INCY
- CAH
- ELV
- SOLV
- BMY
- DXCM
- CVS
- HSIC
- VTRS
- JNJ
- DVA
- UHS
- CI
- BIIB
- VRTX
- REGN
- CNC
- MRK
- EW
- HUM
- MCK
- COR
- AMGN
- WAT
- WST
- TECH
- IDXX
- DGX
- RVTY
- MTD
- A
- ZBH
- ISRG
- TMO
- ALGN
- HCA
- UNH
- COO
- BDX
- VEEV
- MDT
- DHR
- PFE
- LH
- RMD
- IQV
- GEHC
- STE
- PODD
- BSX
- SYK
- BAX
- CRL
- ZTS
- ABT
- GILD
- EBAY
- KDP
More on AbbVie
AbbVie is in the Healthcare sector. On the model's multifactor score of Oct 21, 2026 it ranks 201 of 464, and 27 of the 55 companies in its sector that score. It is a quantitative model ranking, not a recommendation.
All ~500 S&P 500 companies, sorted by when they report →
Guide: 10-K, 10-Q and 8-K · all guides
What is behind these dates
The concepts on this page, explained from scratch in the Academy. Free, no account.
- Guessing next quarter's earnings gives no edgeWhy knowing a quarter's earnings in advance is not enough to make money: what moves the price is the gap against what was expected.
- Supply, demand and price: why it rises and falls constantlyWhat happens to the price on announcement day, and why excellent results can leave the stock falling.
- The three financial statements of a companyWhat is inside the 10-Q and the 10-K whose lag behind the announcement this page measures.
- Point-in-time data and look-ahead biasWhy the date a figure became public matters as much as the figure, which is exactly the distinction behind the two date columns above.
Source: EDGAR, the SEC's public database (forms 8-K, 10-Q and 10-K). Data through Oct 5, 2026. This is a list of public facts and of calculations made on them, not financial advice or a recommendation to buy or sell.